Universitätsklinikum Heidelberg

Evaluation of pregnancies after allogeneic stem cell transplantation during the last 15years in Germany (2020) Sockel K, Frank S, Neu A, Ditschkowski M, Hilgendorf I, Goeckenjan M, Stoelzel F, et al. Conference contribution Allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia with ASXL1-, RUNX1- and TP53 mutations (2020) Egger-Heidrich K, Middeke JM, Schaefer-Eckart K, Kaufmann M, Einsele H, Mueller-Tidow C, Rösler W, et al. Conference contribution Real-world management and outcome of thymic carcinomas in a tertiary German thoracic oncology center (2020) Margineanu A, Bulut E, Rieker R, Winter H, Eichhorn M, Heussel CP, Herth F, et al. Conference contribution Registry Research Funding of the German Society of Plastic, Reconstructive and Aesthetic Surgeons (DGPRaC) and Research Funding Report 2019/2020 (2020) Moellhoff N, Prantl L, Behr B, Beier JP, Daigeler A, Dragu A, Eisenhardt SU, et al. Journal article Mycobacterial Cord Factor Reprograms the Macrophage Response to IFN-γ towards Enhanced Inflammation yet Impaired Antigen Presentation and Expression of GBP1 (2020) Huber A, Killy B, Grummel N, Bodendorfer B, Paul S, Wiesmann V, Naschberger E, et al. Journal article, Original article Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, et al. Journal article CAMK1D triggers immune resistance of human tumor cells refractory to anti-PD-L1 treatment (2020) Volpin V, Michels T, Sorrentino A, Menevse AN, Knoll G, Ditz M, Milenkovic VM, et al. Journal article Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al. Conference contribution Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020) Hauke J, Ernst C, Fasching P, Jackisch C, Seither F, Klare P, Rhiem KE, et al. Conference contribution